Management of advanced stage Hodgkin lymphoma.
Management of advanced stage Hodgkin lymphoma.
复制标题
晚期霍奇金淋巴瘤的治疗。
DOI:
10.6004/jnccn.2006.0023
复制
发表时间:
2006
期刊:
影响因子:
--
通讯作者:
S. Horning
中科院分区:
文献类型:
--
作者:
R. Advani;W. Ai;S. Horning
Although advanced Hodgkin lymphoma is highly curable, balancing the high cure rate with long-term toxicity is challenging. ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) is the standard chemotherapy regimen, producing a high cure rate with acceptable toxicity. Stanford V and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) are new regimens with encouraging results and are undergoing randomized clinical trials. The International Prognostic Score provides a clinical tool that may help identify patients with high-risk disease who may require a more aggressive regimen. Consolidative radiation's role in managing advanced Hodgkin lymphoma is still controversial, but it is most accepted for bulky or residual disease or after brief chemotherapy. The development and integration of newer imaging tools, such as fluorodeoxyglucose-positron emission tomography imaging, may allow a more precise evaluation of disease and help define which patients might benefit from consolidative treatment.
登录
查看更多内容
影响因子:
39.2
作者:
Hancock,SL;Hoppe,RT;Horning,SJ;Rosenberg,SA
通讯作者:
Rosenberg,SA
影响因子:
45.3
作者:
Horning, SJ;Wiliams, J;Cassileth, P
通讯作者:
Cassileth, P
影响因子:
45.3
作者:
Duggan, DB;Petroni, GR;Peterson, BA
通讯作者:
Peterson, BA
DOI:
10.1200/jco.2002.20.3.630
发表时间:
2002
期刊:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子:
--
作者:
Horning,SandraJ;Hoppe,RichardT;Breslin,Sheila;Bartlett,NancyL;Brown,BWilliam;Rosenberg,SaulA
通讯作者:
Rosenberg,SaulA